PRETERM BIRTH AND PROM TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Market News

Recent Developments

New product launches

• In April 2023, Mediclinic Southern Africa, a private hospital company, announced the launch of safe, non-invasive prenatal testing (NIPT) for pregnant parents as part of its DNA-based diagnostic and clinical interpretation services. This is a new product that was added once Mediclinic Ancestry testing was introduced in 2023.
• In October 2022, Ambry Genetics, a clinical diagnostic testing company and a division of REALM IDx, a biotechnology company, launched a new reproductive health initiative powered by its Comprehensive Assessment Risk and Education (CARE) Program, a digital platform designed to increase access to non-invasive prenatal testing (NIPT), also known as carrier screening, and support patients in making decisions.
• In July 2022, GE Healthcare, a medical technology company, launched its most advanced ultrasound, the next-generation Voluson Expert 22. This latest addition to GE Healthcare’s award-winning Women’s Health portfolio utilizes graphic-based beam former technology, which produces higher quality images and offers greater flexibility in imaging functions during pregnancy.

Acquisitions and partnerships

• In February 2022, Sera Prognostics Inc., a pregnancy company focused on improving maternal and neonatal health by providing innovative pregnancy biomarker, announced the execution of a partnership with MultiPlan, a healthcare management company. The agreement will help expand access to the PreTRM Test, the company’s proprietary proteomic blood test for measuring a woman’s risk of spontaneous preterm birth.
• In January 2022, QIAGEN N.V., a clinical diagnostic company, announced a partnership with Atila BioSystems, a biotechnology company, to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN N.V’s dPCR franchise. NIPT requires only a blood sample from the mother, and replaces more invasive testing methods such as amniocentesis that can endanger the fetus and mother.
• In June 2019, Invitae Corporation, a medical genetics company, announced that it has entered into a definitive agreement to acquire Singular Bio, Inc., a privately-held company developing single molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive prenatal screening (NIPS)